AKT1 and ovarian cancer: For EC, 61% have mutations in the PI3K pathway genes, including PIK3CA, PTEN, PIK3R1, PIK3R2, and AKT1. 24Our results confirmed that PIK3CA is druggable in certain populations and mostly targetable in nonserous ovarian cancer.